SUPN - Why Supernus Pharmaceuticals Stock Is Rising Today
Shares of Supernus Pharmaceuticals (NASDAQ: SUPN) are up by 16.7% as of 2:18 p.m. EST on Wednesday after rising by as much as 22.4% earlier today. Investors are bidding up shares of the biopharmaceutical company following its release of positive results from a phase 3 clinical trial for one of its leading pipeline candidates.
A phase 3 trial investigating the efficacy of Supernus Pharmaceuticals' SPN-812 on adults with attention deficit hyperactivity disorder (ADHD) showed that the medicine was able to improve the symptoms of the condition when compared to the placebo, which was the study's primary endpoint. The drugmaker also reported that SPN-812 had a favorable safety profile throughout the study. Note that this medicine has already been reviewed by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in patients between the ages of 6 and 17.
Image source: Getty Images.
For further details see:
Why Supernus Pharmaceuticals Stock Is Rising Today